Navigation Links
Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Date:10/1/2013

NEW YORK, Oct. 1, 2013 /PRNewswire/ -- Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the final closing of a Series A financing raising $8 million in gross proceeds.  The offer was oversubscribed and Laidlaw & Company (UK) Ltd. acted as the exclusive placement agent.   

The company intends to use the Series A proceeds to continue the development of its product pipeline and for general corporate activities.  "This impressive response from investors clearly shows the potential of our diversified product portfolio of drug candidates aimed to address the significant unmet medical need in chronic pain," said Sergio Traversa, CEO of Relmada.  Based on this successful offering, we plan to complete the required steps for LevoCap ER to enter Phase III of development, d-methadone to enter Phase IIb, MepiGel and BuCap to start the pilot PK studies and to prepare the company for a public transaction in the first half of 2014.

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical stage, private biopharmaceutical company with a diversified portfolio of four products and a deep early stage pipeline for the treatment of pain.  Relmada's strategy focuses on two complementary pillars: the improvement of proven drug candidates with novel delivery methods and pharmaceutical compositions and the development of d-methadone as an innovative NMDA (N-Methyl-D-aspartate) inhibitor platform. 

The Company is currently developing several drug candidates including: LevoCap ER, its abuse resistant, once–a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for diabetic painful neuropathy (DPN); BuCap, its oral dosage form of the opioid analgesic buprenorphine; MepiGel, its FDA Orphan Drug designated topica
'/>"/>

SOURCE Relmada Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... growth in the in vitro diagnostic (IVD) test industry, ... Kalorama Information. The healthcare market researcher listed more than 25 ... that could be the future of IVD products. Kalorama details ... industry, The Worldwide Market for In Vitro Diagnostic ...
(Date:10/22/2014)... The Americas Inorganic Refrigerants Market report defines and ... analysis and forecast of revenue. , Browse through ... report, to get an idea of the in-depth ... the segmentation in the Americas inorganic refrigerants market, ... , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html , Inorganic refrigerants ...
(Date:10/22/2014)... Arlington, Massachusetts (PRWEB) October 22, 2014 ... recently announced the release of a new infographic, ... was to create a beautifully designed, easy to follow ... Ebola's transmission, areas of outbreak, symptoms and prevention. , ... have discovered that the 2014 Ebola outbreak represents not ...
(Date:10/22/2014)... 22, 2014 Grace Century, a private ... projects, announces the addition of Dr. Yousef “Josh” ... advisory team. Dr. Siddiqui will provide further healthcare expertise ... graduate of University College Medical School in ... medicine in 2001. With further certification as a General ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2
... Cell Therapeutics, Inc.,("CTI" or the "Company") (Nasdaq: ... institutional investor shall purchase, for $14.2 million, newly,issued 15.5% ... of,$1.27 per share. The transaction is the result of ... on September 26, 2008) under which,the investor had purchased ...
... Qi Lu, former EVP of,Yahoo!, continues to dedicate his passion ... HYSTA, USA. HYSTA is greatly,honored to have Qi,s on-going commitment ... August, he had served more than 10,years, which was a ... that has not changed is his dedication to serve the ...
... RainDance Technologies,Inc., a provider of innovative droplet-based ... today dedicated its new headquarters and,operations building ... Keynoting the event was Sir Richard ... medicine and Founder and Chief Scientific Officer ...
Cached Biology Technology:Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes 2Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes 3Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA 2RainDance Dedicates New Headquarters, Manufacturing Facility 2RainDance Dedicates New Headquarters, Manufacturing Facility 3
(Date:10/25/2014)... , Oct. 23, 2014 Research ... "Biometrics Market in Europe 2014-2018" report to their ... helps to assess individuals on the basis of their ... identification of both physiological traits such as fingerprints, face ... and behavioral traits such as keystroke patterns and speech ...
(Date:10/19/2014)... electricity access in India over the last 30 ... carbon emissions growth during that time, according to ... Nature Climate Change ., "Energy access is fundamental ... of life, including education, communication, and health," says ... , While increased energy access is widely agreed ...
(Date:10/17/2014)... This news release is available in German . ... need millions of sperms every day in order to reproduce? ... questions are the topic of the latest issue of the ... 16th, 2014). The evolutionary biologist Steven Ramm from Bielefeld University ... nature, it is not unusual for a female to copulate ...
Breaking Biology News(10 mins):Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Improved electricity access has little impact on climate change 2Sperm wars 2
... one day in the distant future, miniature, medically-savvy computers ... them on the spot by releasing a suitable drug, ... reality, computers must be sufficiently small to fit into ... to various cellular systems. These challenges can be best ...
... HOLE, MASS. -- Among the animals that are appealing ... to mind. Slender, limbless, primitive blobs that look pretty ... boring. I wouldn,t recommend them for a home aquarium," ... Biological Laboratory (MBL). Yet Nasi and his collaborators managed ...
... Darwin on the Galapagos Islands, researchers have been interested ... particular island, can lead to the formation of new ... selection is a process whereby heritable traits that enhance ... heritable traits become less common. Over time, animals and ...
Cached Biology News:A genetic device performs DNA diagnosis 2Sensing the light, but not to see 2LSU professor discovers how new corals species form in the ocean 2LSU professor discovers how new corals species form in the ocean 3